# **Electronic Supplementary Information (ESI)**

# The discovery of novel imidazo[1,2-a]pyridine derivatives as covalent anticancer agents

Qin Song,<sup>[a]#</sup> Qianer Zhang,<sup>[a]#</sup> Xuejing Fan,<sup>[a]</sup> Fatmata Kayaat,<sup>[a]</sup> Ruicheng Lv,<sup>[a]</sup> Jing Li,<sup>\*[a]</sup> and Yong Wang<sup>\*[a]</sup> <sup>[a]</sup> Key Laboratory of Marine Drugs, Chinese Ministry of Education; School of Medicine and Pharmacy, Ocean University of China, Qingdao 26003, Shandong, P. R. China; Laboratory for Marine Drugs and Bioproducts, Pilot National Laboratory for Marine Science and Technology, Qingdao 266200, P. R. China # These two authors contributed equally

#### **Table of contents**

1. Synthesis of compounds	<b>S1-S7</b>
2. <sup>1</sup> H and <sup>13</sup> C NMR spectra of compounds synthesized	S8-S24
3. MS and HRMS spectra of compounds synthesized	S25-S30
4. HPLC analysis for target compounds	S31-S39
5. 2D docking model of I-11	S40

#### 1. Synthesis of compounds

1-(4-(3-(tert-butylamino)-2-(naphthalen-1-yl)imidazo[1,2-a]pyridin-8-yl)piperazin-1-yl)prop-2-en -1-one (**I-2**)

Following the synthetic method of **I-1**, compound **I-2** was obtained as a yellow solid in 56% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  8.03 (d, *J* = 7.5 Hz, 1H), 7.96 – 7.85 (m, 3H), 7.67 (dd, *J* = 7.0, 1.1 Hz, 1H), 7.55 (dd, *J* = 8.1, 7.1 Hz, 1H), 7.51 – 7.44 (m, 2H), 6.74 (t, *J* = 7.1 Hz, 1H), 6.60 (dd, *J* = 16.8, 10.5 Hz, 1H), 6.46 (d, *J* = 6.9 Hz, 1H), 6.31 (dd, *J* = 16.8, 1.9 Hz, 1H), 5.71 (dd, *J* = 10.5, 1.9 Hz, 1H), 4.01 – 3.88 (m, 2H), 3.85 – 3.76 (m, 2H), 3.72 – 3.65 (m, 2H), 3.51 (s, 2H), 0.74 (s, 9H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  165.38, 139.97, 137.52, 137.03, 133.82, 131.97, 128.51, 128.40, 128.21, 128.00, 127.40, 126.34, 125.69, 125.36, 117.70, 55.81, 50.13, 49.21, 45.88, 41.76, 29.74. ESI-LCMS (m/z): [M+H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>32</sub>N<sub>5</sub>O 454.25; found 454.08. 1-(4-(3-(tert-butylamino)-2-(1*H*-indazol-7-yl)imidazo[1,2-a]pyridin-8-yl)piperazin-1-yl)prop-2-en -1-one (**I-3**)

Following the synthetic method of **I-1**, compound **I-3** was obtained as a yellow solid in 55% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  8.31 (s, 1H), 8.11 (s, 1H), 8.03 (d, *J* = 8.7 Hz, 1H), 7.93 (d, *J* = 6.7 Hz, 1H), 7.50 (d, *J* = 8.7 Hz, 1H), 6.69 (t, *J* = 7.1 Hz, 1H), 6.63 (dd, *J* = 16.8, 10.6 Hz, 1H), 6.41 (d, *J* = 7.3 Hz, 1H), 6.33 (dd, *J* = 16.8, 1.8 Hz, 1H), 5.73 (dd, *J* = 10.5, 1.8 Hz, 1H), 3.96 (s, 2H), 3.84 (s, 2H), 3.66 (s, 2H), 3.50 (s, 2H), 1.01 (s, 9H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  165.50, 139.90, 137.98, 137.31, 135.19, 128.11, 127.89, 127.45, 123.66, 120.25, 117.56, 111.49, 109.55, 55.18, 50.12, 49.28, 45.90, 41.81, 30.40. ESI-LCMS (m/z): [M+H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>30</sub>N<sub>7</sub>O 444.24; found 444.08.

1-(4-(3-(tert-butylamino)-2-(2-fluoro-6-hydroxyphenyl)imidazo[1,2-a]pyridin-8-yl)piperazin-1-yl) prop-2-en-1-one (**I-4**)

Following the synthetic method of **I-1**, compound **I-4** was obtained as a yellow solid in 39% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  8.09 (d, J = 6.8 Hz, 1H), 7.23 – 7.14 (m, 1H), 6.89 – 6.82 (m, 1H), 6.77 (t, J = 7.1 Hz, 1H), 6.70 – 6.65 (m, 1H), 6.64 – 6.57 (m, 1H), 6.50 (d, J = 7.3 Hz, 1H), 6.34 (dd, J = 16.8, 1.8 Hz, 1H), 5.74 (dd, J = 10.5, 1.8 Hz, 1H), 3.96 (s, 2H), 3.84 (s, 2H), 3.57 (s, 2H), 3.40 (s, 2H), 1.00 (s, 9H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  165.14, 160.85, 157.42, 138.96, 136.42, 129.38 – 128.54 (m), 127.65, 127.12, 125.75, 117.69, 112.47, 112.17 – 111.48 (m),

108.29, 106.02 (d, J = 24.0 Hz), 55.92, 49.76, 48.93, 45.52, 41.46, 29.32. ESI-LCMS (m/z): [M]<sup>+</sup> calculated for C<sub>24</sub>H<sub>28</sub>FN<sub>5</sub>O<sub>2</sub> 437.22; found 437.93.

1-(4-(3-((2,6-dimethylphenyl)amino)-2-(2-fluoro-6-hydroxyphenyl)imidazo[1,2-a]pyridin-8-yl)pip erazin-1-yl)prop-2-en-1-one (**I-5**)

Following the synthetic method of **I-1**, compound **I-5** was obtained as a yellow solid in 41% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  7.31 (d, *J* = 6.7 Hz, 1H), 7.15 (q, *J* = 8.2 Hz, 1H), 6.90 (d, *J* = 7.5 Hz, 2H), 6.83 (d, *J* = 8.1 Hz, 1H), 6.77 (t, *J* = 7.5 Hz, 1H), 6.69 – 6.65 (m, 1H), 6.64 – 6.56 (m, 2H), 6.48 (d, *J* = 7.4 Hz, 1H), 6.34 (dd, *J* = 16.8, 1.7 Hz, 1H), 5.75 (dd, *J* = 10.5, 1.7 Hz, 1H), 5.68 (d, *J* = 6.1 Hz, 1H), 3.97 (s, 2H), 3.84 (s, 2H), 3.60 (s, 2H), 3.42 (s, 2H), 1.90 (s, 6H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  165.61, 161.05, 158.62, 157.46, 139.64, 139.14, 135.46, 132.02, 129.66 (d, *J* = 11.7 Hz), 129.57, 128.37, 127.26, 126.69, 123.82, 121.59, 116.34, 113.22, 112.60, 107.97, 106.57, 106.33, 50.09, 49.08, 45.89, 41.76, 18.32. ESI-LCMS (m/z): [M]<sup>+</sup> calculated for C<sub>28</sub>H<sub>28</sub>FN<sub>5</sub>O<sub>2</sub> 485.22; found 485.93.

Ethyl{[2-(6-fluoro-2-hydroxyphenyl)-8-[4-(1-oxoprop-2-enyl)piperazin-1-yl]imidazo[3,2-*a*]pyridi n-3-yl]amino}acetate (**I-6**)

Following the synthetic method of **I-1**, compound **I-6** was obtained as a yellow solid in 49% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  7.93 (d, *J* = 6.7 Hz, 1H), 7.18 (q, *J* = 7.7 Hz, 1H), 6.82 (dd, *J* = 11.0, 7.8 Hz, 2H), 6.72 – 6.66 (m, 1H), 6.60 (dd, *J* = 16.7, 10.6 Hz, 1H), 6.51 (d, *J* = 7.4 Hz, 1H), 6.32 (d, *J* = 16.8 Hz, 1H), 5.75 – 5.69 (m, 1H), 4.08 (q, *J* = 7.1 Hz, 2H), 3.93 (s, 2H), 3.82 (s, 2H), 3.69 (d, *J* = 3.4 Hz, 2H), 3.54 (s, 2H), 3.38 (s, 2H), 1.17 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  170.87, 165.54, 139.55, 135.87, 129.62, 129.51 (d, *J* = 14.7 Hz), 128.25, 127.32, 126.91, 116.81, 113.09, 113.06, 108.61, 106.45, 106.21, 61.24, 49.37, 49.12, 14.05. ESI-LCMS (m/z): [M+H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>27</sub>FN<sub>5</sub>O<sub>4</sub> 468.20; found 468.17.

1-(4-(3-(tert-butylamino)-2-(2-fluoro-6-hydroxyphenyl)imidazo[1,2-a]pyridin-8-yl)piperazin-1-yl) -2-chloroethan-1-one (**I-7**)

Intermediate 9 (0.07 g, 0.14 mmol) was dissolved in anhydrous DCM, and then NaHCO<sub>3</sub> (0.012 g, 0.14 mmol) was added as follows. The chloroacetyl chloride (23  $\mu$ L, 0.14 mmol) was added to the above system at low temperature. The mixture was stirred for 0.5 h. Pour the mixture into water (10 mL) and extract with ethyl acetate (10 mL × 3), the combined organic phase was

washed with water (10 mL × 3), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. Purification of the residue by flash column chromatography using DCM/MeOH as the gradient elution to afford compound **I-7** as a yellow solid in 50% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  8.12 (d, *J* = 6.7 Hz, 1H), 7.22 – 7.15 (m, 1H), 6.85 (d, *J* = 8.2 Hz, 1H), 6.79 (t, *J* = 7.1 Hz, 1H), 6.68 (dd, *J* = 11.2, 8.3 Hz, 1H), 6.54 (d, *J* = 7.3 Hz, 1H), 4.13 (s, 2H), 3.92 – 3.87 (m, 2H), 3.83 – 3.78 (m, 2H), 3.60 (s, 2H), 3.42 – 3.36 (m, 2H), 1.00 (s, 9H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  165.30, 158.79, 157.75, 139.12, 136.54, 129.56 (d, *J* = 11.7 Hz), 118.30, 112.95, 112.23, 106.59, 106.35, 56.42, 49.98, 49.14, 46.45, 42.04, 40.85, 29.71. ESI-LCMS (m/z): [M]<sup>+</sup> calculated for C<sub>23</sub>H<sub>27</sub>ClFN<sub>5</sub>O<sub>2</sub> 459.18; found 459.95.

1-(4-(3-(tert-butylamino)-2-(2-fluoro-6-hydroxyphenyl)imidazo[1,2-a]pyridin-8-yl)piperazin-1-yl) prop-2-yn-1-one (**I-8**)

Intermediate **9** (0.07 g, 0.14 mmol) was dissolved in anhydrous DCM and pre-cooled in an icewater bath, then DIPEA (27 µL, 0.28 mmol) was added to another reaction vial. The HBTU (0.011 g, 0.03 mmol), and propargylate (8 µL, 0.12 mmol) was added dropwise slowly. After activation for 3 h, the mixture of incorporating propargylate was added dropwise into the pre-cooled reaction vial. The reaction was partitioned between DCM and water. The organic layer was separated, washed with water and brine, and concentrated in vacuo. Purification by flash column chromatography on silica gel using DCM/MeOH as the gradient elution to obtain **I-8** as a yellow solid in 43% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  8.11 (d, *J* = 6.4 Hz, 1H), 7.22 – 7.16 (m, 1H), 6.86 (d, *J* = 8.2 Hz, 1H), 6.78 (t, *J* = 7.1 Hz, 1H), 6.68 (dd, *J* = 11.5, 8.0 Hz, 1H), 6.52 (d, *J* = 7.2 Hz, 1H), 4.08 – 4.03 (m, 2H), 3.94 – 3.89 (m, 2H), 3.58 (s, 2H), 3.42 – 3.37 (m, 2H), 3.16 (s, 1H), 1.01 (s, 9H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  160.80, 157.33, 151.48, 138.76, 136.34, 129.39, 129.01 (d, *J* = 11.7 Hz), 117.78, 112.41, 111.81, 108.47, 105.95, 79.61, 74.84, 55.83, 49.59, 48.64, 46.56, 40.92, 29.52. ESI-LCMS (m/z): [M]<sup>+</sup> calculated for C<sub>24</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>2</sub> 435.21; found 435.99.

1-(4-(3-(tert-butylamino)-2-(naphthalen-1-yl)imidazo[1,2-a]pyridin-8-yl)piperazin-1-yl)prop-2-yn -1-one (**I-9**)

Following the synthetic method of **I-8**, compound **I-9** was obtained as a pale green solid in 41% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  8.04 (d, *J* = 6.7 Hz, 1H), 7.97 – 7.89 (m, 2H), 7.88 (d, *J* = 8.2 Hz, 1H), 7.67 (d, *J* = 6.9 Hz, 1H), 7.57 – 7.53 (m, 1H), 7.51 – 7.45 (m, 2H), 6.74 (t, *J* = 7.1

Hz, 1H), 6.46 (d, J = 7.3 Hz, 1H), 4.06 – 3.99 (m, 2H), 3.93 – 3.87 (m, 2H), 3.73 – 3.68 (m, 2H), 3.57 – 3.51 (m, 2H), 3.14 (s, 1H), 0.75 (s, 9H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  151.81, 139.88, 137.56, 133.87, 132.01, 128.56, 128.42, 128.25, 126.38, 125.82, 125.72, 125.40, 117.89, 111.43, 79.44, 75.40, 55.87, 50.03, 49.07, 47.03, 41.39, 29.78. ESI-LCMS (m/z): [M]<sup>+</sup> calculated for C<sub>28</sub>H<sub>29</sub>N<sub>5</sub>O 451.24; found 451.99.

1-(4-(3-((2,6-dimethylphenyl)amino)-2-(2-fluoro-6-hydroxyphenyl)imidazo[1,2-a]pyridin-8-yl)pip erazin-1-yl)prop-2-yn-1-one (**I-10**)

Following the synthetic method of **I-8**, compound **I-10** was obtained as a pale green solid in 53% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  7.32 (d, J = 6.6 Hz, 1H), 7.15 (q, J = 8.2 Hz, 1H), 6.90 (d, J = 7.5 Hz, 2H), 6.83 (d, J = 8.2 Hz, 1H), 6.77 (t, J = 7.5 Hz, 1H), 6.68 (t, J = 7.1 Hz, 1H), 6.63 – 6.57 (m, 1H), 6.49 (d, J = 7.4 Hz, 1H), 5.69 (d, J = 6.1 Hz, 1H), 4.08 – 4.03 (m, 2H), 3.94 – 3.89 (m, 2H), 3.63 – 3.58 (m, 2H), 3.44 – 3.39 (m, 2H), 3.17 (s, 1H), 1.90 (s, 6H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  158.60, 157.43, 151.91, 139.49, 139.09, 135.41, 129.68 (d, J = 11.6 Hz), 129.56, 126.70, 123.88, 121.62, 116.52, 113.16, 112.60, 108.16, 106.57, 106.33, 79.69, 75.23, 50.00, 48.89, 46.98, 41.31, 29.70. ESI-LCMS (m/z): [M]<sup>+</sup> calculated for C<sub>28</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>2</sub> 483.21; found 483.74.

1-(4-(2-(2-fluoro-6-hydroxyphenyl)-3-((2-(trifluoromethyl)benzyl)amino)imidazo[1,2-a]pyridin-8 -yl)piperazin-1-yl)prop-2-yn-1-one (**I-11**)

Following the synthetic method of **I-8**, compound **I-11** was obtained as a yellow solid in 50% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  7.95 – 7.90 (m, 1H), 7.50 (d, *J* = 7.7 Hz, 1H), 7.29 (t, *J* = 7.5 Hz, 1H), 7.19 (t, *J* = 7.6 Hz, 1H), 7.12 – 7.05 (m, 1H), 7.03 (d, *J* = 7.6 Hz, 1H), 6.84 (t, *J* = 7.1 Hz, 1H), 6.73 (d, *J* = 8.1 Hz, 1H), 6.58 – 6.52 (m, 2H), 4.16 (s, 2H), 4.06 – 4.03 (m, 2H), 3.93 – 3.89 (m, 2H), 3.60 – 3.56 (m, 2H), 3.43 – 3.39 (m, 2H), 3.17 (s, 1H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  160.57, 157.63, 151.93, 139.51, 136.71, 136.13, 131.63, 130.58, 129.30 (d, *J* = 11.9 Hz), 127.68, 127.03, 125.95 (d, *J* = 5.6 Hz), 116.70, 113.03, 112.78, 108.54, 106.28, 106.04, 79.67, 75.27, 50.00, 48.90, 47.02, 41.35, 29.72. ESI-HRMS (m/z): [M+H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>24</sub>F<sub>4</sub>N<sub>5</sub>O<sub>2</sub> 538.1866; found 538.1861.

1-{8-[2-(6-fluoro-2-hydroxyphenyl)-3-({[2-(trifluoromethyl)phenyl]methyl}amino)imidazo[3,2-*a*] pyridin-8-yl]-3,8-diazabicyclo[3.2.1]octan-3-yl}prop-2-yn-1-one (**I-12**)

Following the synthetic method of **I-8**, compound **I-12** was obtained as a yellow solid in 43% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  7.91 (d, J = 7.4 Hz, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.31 (t, J = 7.6 Hz, 1H), 7.21 (t, J = 7.7 Hz, 1H), 7.09 (q, J = 8.3, 7.5 Hz, 2H), 6.84 – 6.79 (m, 1H), 6.74 (d, J = 8.0 Hz, 1H), 6.55 (dd, J = 11.9, 8.8 Hz, 1H), 6.46 (d, J = 7.3 Hz, 1H), 4.86 (d, J = 6.5 Hz, 1H), 4.68 (d, J = 5.3 Hz, 1H), 4.32 (d, J = 11.3 Hz, 1H), 4.18 – 4.09 (m, 2H), 3.81 (d, J = 13.0 Hz, 1H), 3.14 (d, J = 10.3 Hz, 1H), 3.06 (d, J = 13.5 Hz, 2H), 2.33 – 2.26 (m, 1H), 2.23 – 2.12 (m, 2H), 2.11 – 2.04 (m, 1H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  160.58, 158.16, 157.62, 148.71, 139.66, 136.86, 136.74, 136.16, 131.65, 130.56, 129.28 (d, J = 11.9 Hz), 127.68, 127.02, 125.97 (d, J = 5.7 Hz), 116.25, 113.11, 112.71, 108.40, 106.33, 106.10, 77.26, 75.97, 56.92, 55.95, 54.33, 51.96, 48.70, 27.81, 27.27. ESI-LCMS (m/z): [M]<sup>+</sup> calculated for C<sub>30</sub>H<sub>25</sub>F<sub>4</sub>N<sub>5</sub>O<sub>2</sub> 563.19; found 563.75. 1-{7-[2-(6-fluoro-2-hydroxyphenyl)-3-({[2-(trifluoromethyl)phenyl]methyl}amino)imidazo[3,2-*a*]

pyridin-8-yl]-2,7-diazaspiro[3.5]nonan-2-yl}prop-2-yn-1-one (I-13)

Following the synthetic method of **I-8**, compound **I-13** was obtained as a yellow solid in 48% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  7.89 (d, *J* = 6.6 Hz, 1H), 7.51 (d, *J* = 7.8 Hz, 1H), 7.30 (t, *J* = 7.3 Hz, 1H), 7.20 (t, *J* = 7.7 Hz, 1H), 7.12 – 7.02 (m, 2H), 6.81 (t, *J* = 7.1 Hz, 1H), 6.74 (d, *J* = 8.2 Hz, 1H), 6.54 (dd, *J* = 11.2, 8.2 Hz, 2H), 4.16 (d, *J* = 4.7 Hz, 2H), 3.99 (s, 2H), 3.84 (s, 2H), 3.48 – 3.42 (m, 2H), 3.37 (dt, *J* = 11.9, 5.3 Hz, 2H), 3.00 (s, 1H), 2.05 (t, *J* = 5.4 Hz, 4H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  158.17, 157.83, 153.28, 140.24, 136.81, 136.27, 131.61, 130.55, 129.15(d, *J* = 12.0 Hz), 127.63, 126.86, 125.93 (d, *J* = 5.6 Hz), 116.08, 113.10, 112.80, 108.29, 106.18, 105.94, 77.86, 74.77, 60.29, 57.91, 46.81, 35.25, 34.38, 29.71. ESI-LCMS (m/z): [M+H]<sup>+</sup> calculated for C<sub>31</sub>H<sub>28</sub>F<sub>4</sub>N<sub>5</sub>O<sub>2</sub> 578.21; found 578.83.

1-(4-(2-(2-fluoro-6-hydroxyphenyl)-3-((4-isopropylbenzyl)amino)imidazo[1,2-a]pyridin-6-yl)pipe razin-1-yl)prop-2-yn-1-one (**I-14**)

Following the synthetic method of **I-8**, compound **I-14** was obtained as a reddish brown solid in 33% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  7.56 (s, 1H), 7.44 (d, *J* = 9.6 Hz, 1H), 7.15 – 7.06 (m, 6H), 6.81 (d, *J* = 8.2 Hz, 1H), 6.65 – 6.58 (m, 1H), 3.96 (d, *J* = 10.3 Hz, 4H), 3.83 (s, 2H), 3.19 (s, 1H), 3.05 (d, *J* = 18.4 Hz, 4H), 2.88 – 2.81 (m, 1H), 1.20 (d, *J* = 6.8 Hz, 6H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  165.15, 148.46, 139.20, 136.64, 128.38, 126.80, 126.29, 125.96, 121.85 (d, *J* = 30.6 Hz), 116.39, 108.98, 79.81, 75.11, 50.65, 49.93, 46.07, 41.84, 40.77, 33.75, 24.02. ESI- LCMS (m/z): [M]<sup>+</sup> calculated for C<sub>30</sub>H<sub>30</sub>FN<sub>5</sub>O<sub>2</sub> 511.24; found 511.90.

1-(4-(3-((4-isopropylbenzyl)amino)-2-(thiophen-2-yl)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)pr op-2-yn-1-one (**I-15**)

Following the synthetic method of **I-8**, compound **I-15** was obtained as a yellow solid in 42% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  7.73 (d, J = 2.2 Hz, 1H), 7.67 (d, J = 5.0 Hz, 1H), 7.44 (d, J = 9.6 Hz, 1H), 7.39 (dd, J = 4.9, 2.9 Hz, 1H), 7.27 (s, 1H), 7.23 (d, J = 8.1 Hz, 2H), 7.18 (d, J = 8.1 Hz, 2H), 6.96 (dd, J = 9.6, 1.9 Hz, 1H), 4.16 (s, 2H), 3.95 – 3.89 (m, 2H), 3.82 – 3.77 (m, 2H), 3.19 (s, 1H), 3.00 – 2.95 (m, 2H), 2.93 – 2.90 (m, 2H), 2.90 – 2.85 (m, 1H), 1.23 (d, J = 6.9 Hz, 6H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  165.51, 136.80, 128.63, 128.52, 127.25, 126.97, 126.39, 126.06, 125.96, 109.02, 52.40, 51.05, 50.22, 45.68, 33.91, 24.16. ESI-LCMS (m/z): [M+H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>30</sub>N<sub>5</sub>OS 484.21; found 484.01.

1-(4-(2-(2-hydroxynaphthalen-1-yl)-3-((4-isopropylbenzyl)amino)imidazo[1,2-a]pyridin-6-yl)pipe razin-1-yl)prop-2-yn-1-one (**I-16**)

Following the synthetic method of **I-8**, compound **I-16** was obtained as a yellow solid in 36% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  7.81 (d, *J* = 8.0 Hz, 1H), 7.75 – 7.69 (m, 2H), 7.52 (s, 1H), 7.46 (t, *J* = 9.2 Hz, 2H), 7.33 (t, *J* = 7.4 Hz, 1H), 7.23 (d, *J* = 8.8 Hz, 1H), 7.07 (d, *J* = 11.6 Hz, 1H), 6.93 (d, *J* = 8.0 Hz, 2H), 6.75 (d, *J* = 8.0 Hz, 2H), 3.98 – 3.92 (m, 2H), 3.85 – 3.80 (m, 2H), 3.68 (s, 2H), 3.20 (s, 1H), 3.04 (dt, *J* = 20.7, 4.9 Hz, 4H), 2.80 (s, 1H), 2.79 – 2.73 (m, 1H), 1.16 (d, *J* = 6.9 Hz, 6H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  154.04, 139.40, 135.97, 130.19, 128.77, 127.87, 126.93, 126.37, 123.48, 123.00, 118.84, 116.78, 109.27, 79.84, 51.74, 51.00, 50.22, 46.69, 41.24, 33.63, 29.71, 23.93. ESI-LCMS (m/z): [M+H]<sup>+</sup> calculated for C<sub>34</sub>H<sub>34</sub>N<sub>5</sub>O<sub>2</sub> 544.26; found 544.06.

1-(4-(3-(tert-butylamino)-2-(thiophen-2-yl)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)prop-2-yn-1 -one (I-17)

Following the synthetic method of **I-8**, compound **I-17** was obtained as a yellow solid in 40% yield. <sup>1</sup>H NMR (400 MHz, Chloroform-*d*)  $\delta$  7.75 (s, 1H), 7.68 (s, 1H), 7.64 (d, *J* = 4.6 Hz, 1H), 7.46 (d, *J* = 9.5 Hz, 1H), 7.35 (s, 1H), 7.01 (d, *J* = 9.4 Hz, 1H), 3.97 (s, 2H), 3.84 (s, 2H), 3.18 (s, 1H), 3.12 (s, 2H), 3.06 (s, 2H), 1.11 (s, 9H). <sup>13</sup>C NMR (100 MHz, Chloroform-*d*)  $\delta$  138.83, 127.19, 125.33, 123.82, 122.59, 121.83, 116.91, 110.50, 79.75, 56.51, 51.22, 50.41, 46.80, 41.32, 30.57.

ESI-LCMS (m/z):  $[M+H]^+$  calculated for  $C_{22}H_{26}N_5OS$  408.18; found 407.85.



# 2. $^1H$ and $^{13}C$ NMR spectra of compound I-1 $\sim 17$

<sup>1</sup>H NMR spectrum of compound I-1 (400 MHz, Chloroform-*d*)

210 200 190 180 170 160 150 140 130 120 110 100 f1 (ppm)







### <sup>1</sup>H NMR spectrum of compound I-4 (400 MHz, Chloroform-*d*)

































# 3. MS and HRMS spectra of compounds synthesized

I-1 MS









I-8 MS







I-12 MS



I-13 MS



I-16 MS



# 4. HPLC analysis for target compounds

# Compound I-1

Result			
	Ret. Time	Area	Rel. Area (%)
1	8.232	52715	1.85
2	8.6	81430	2.85
3	8.86	2721148	95.3



# Compound I-2

Result

	Ret. Time	Area	Rel. Area (%)
1	5.948	55431431	95.72
2	6.633	2481496	4.28



Result			
	Ret. Time	Area	Rel. Area (%)
1	4.869	127630	0.96
2	5.522	97082	0.73
3	6.241	12802185	96.64
4	6.727	100173	0.76
5	7.615	120128	0.91
1.0 14 12 18 0.0 0.0 0.0 0.0 0.0		₩ <sup>1</sup> 000 000 000 000 000 000 000 0	10,00 12,00 14,00

# Compound I-4

	Ret. Time	Area	Rel. Area (%)
1	7.071	80589	0.43
2	7.39	18131720	96.22
3	7.747	291545	1.55
4	7.96	340022	1.8



Compound	d I-5
----------	-------

	Ret. Time	Area	Rel. Area (%)
1	7.261	17763681	97.45
2	8.004	465606	2.55



	Ret. Time	Area	Rel. Area (%)
1	5.927	580374	1.12
2	6.264	49847386	96.5
3	7.108	596980	1.16
4	7.338	630957	1.22





### Compound I-8

	Ret. Time	Area	Rel. Area (%)
1	5.541	113418	0.83
2	6.265	13332173	97.29
3	6.738	138315	1.01
4	7.548	119413	0.87
1.80 1.60 1.40 1.20 0.80 0.60 0.40 0.20 0.00	2.00 4.00	6266 67.541 6.738 6.738 6.738	

Result
--------

	Ret. Time	Area	Rel. Area (%)
1	6.061	803336	2.74
2	7.35	28183458	96.17
3	7.661	317647	1.08



# Compound I-10

	Ret. Time	Area	Rel. Area (%)
1	6.806	140404	1.83
2	7.185	7526950	98.17



	Ret. Time	Area	Rel. Area (%)
1	6.012	47594008	96.01
2	6.656	1975372	3.99



Compound I-12

	Ret. Time	Area	Rel. Area (%)
1	7.747	11145736	95.54
2	10.733	520194	4.46



	Ret. Time	Area	Rel. Area (%)
1	6.933	16293	0.21
2	7.435	7652243	99.32
3	7.965	2607	0.03
4	8.172	33171	0.43
1.20 1.00 0.60 0.40 0.20		6.933 7.435 	

Compound I-14

	Ret. Time	Area	Rel. Area (%)
1	8.456	24552481	97.05
2	10.68	745183	2.95



Result			
	Ret. Time	Area	Rel. Area (%)
1	4.981	4194	0.03
2	5.457	62518	0.41
3	5.8	124360	0.81
4	6.087	14947789	97.66
5	6.627	124493	0.81
6	7.019	14154	0.09
7	7.264	28478	0.19
2.00		6.087	
₹ 1.00-			
0.50		4.381 5.457 6.627 7.019	
0.00	2.00 4.00	6.00 8.00 分钟	10.00 12.00 14.00

### Compound I-16

Result			
	Ret. Time	Area	Rel. Area (%)
1	6.59	2548	0.04
2	6.988	3770	0.06
3	7.23	43023	0.65
4	7.628	51274	0.77
5	8.066	6385534	96.13
6	8.617	135128	2.03
7	8.91	21628	0.33
0.0	50	8.066	
N O.			
0.2	20	6.590 6.988 7.230	8.910
0.	0.00 2.00	4.00 6.00 8.00 分钟	10.00 12.00 14.00

Result			
	Ret. Time	Area	Rel. Area (%)
1	6.757	916	0.01
2	7.021	9872017	99.96
3	7.986	2674	0.03
1.40 1.20 1.00 0.80 0.40 0.20 0.00	2.00 4.00	89 -7.986	10.00 12.00 14.00
0.00	2.00 4.00	6.00 8.00 分钟	10.00 12.00 14.00

### 5. 2D docking model of I-11

